Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
Monoclonal antibodies, such as pertuzumab and cetuximab, can block tumor growth in different
ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
help kill them or carry tumor-killing substances to them. Giving pertuzumab together with
cetuximab may kill more tumor cells. This phase I/II trial is studying the side effects and
best dose of pertuzumab when given together with cetuximab and to see how well they work in
treating patients with previously treated locally advanced or metastatic colorectal cancer